215 results about "Low molecular weight heparin" patented technology

The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin are also described.

A method for administration of a substance into the dermis of a mammal is disclosed. The method involves administration into the dermis by injection which results in improved systemic absorption relative to that obtained upon subcutaneous administration of the substance. The substance administered may be a growth hormone, a low molecular weight heparin or a dopamine receptor agonist.

The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same to stimulate cells of the immune system, bone marrow and other organs. The present compounds can be used to enhance vaccination, increase synthesis of and enhance function of blood cell components and enhance anti-neoplastic effects of various agents. The compounds of the invention can be used to produce a variety of further pharmacologic effects.

Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.

The present invention provides composition and methods for the synthesis of low molecular weight heparins and heparinoids. The present invention also provides compositions having substantially homogenous populations of desired heparin molecules, or molecules useful in the synthesis of heparin oligosaccharides.

Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.

The invention relates to a method of treatment of resistance to platelet inhibitors, i.e. a method to overcome resistance of treatment with platelet inhibitors, said method comprising administering a therapeutically effective amount of dipyridamole in combination with a platelet inhibitor and, optionally, in combination with a third antithrombotic component such as direct thrombin inhibitors, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, heparin, low molecular weight heparin, argatroban, bivalrudin, hirulog or polyglycans to a patient in need thereof. The invention further relates to the use of dipyridamole for the manufacture of a pharmaceutical composition for treatment of resistance to platelet inhibitors. The invention also relates to a method to diagnose resistance to treatment with platelet inhibitors, said method comprising measurement of the density of binding of Annexin V on platelets.

The invention discloses a low molecular weight glycosylated chondroitin sulfate, whose weight average molecular weight is 3000-15000Da. The monosaccharide composition comprises acetyl galactosamine (D-GalNAc), glucuronic acid (D-GlcUA), fucose (L-Fuc), or its sulfuric ester (expressed in -OS03<->), wherein the mole ratio of D-GalNAc to D-GlcUA to L-Fuc to -OS03<-> is 1: (1+/-0.3): (1+/-0.3): (3.5+/-0.5). The low molecular weight glycosylated chondroitin sulfate has a strong anti-HIV-1 virus activity, is a gp120 entry inhibitor, and can be used for preventing and/or treating AIDS. The invention also provides a method for preparing the low molecular weight glycosylated chondroitin sulfate and its composition preparation. Glycosylated chondroitin sulfate is depolymerized by the peroxide method to obtain a low molecular weight product, and then low molecular and/or high-molecular impurities of the product are removed by gel separation or ultrafiltration method. The low molecular weight glycosylated chondroitin sulfate and its medicinal composition can be prepared in the form of an injection, a lyophilized powder or a suppository.

The invention relates to a method for treatment of unstable coronary artery disease, which is characterised by an early revascularisation together with administration of a low molecular weight heparin. Preferably the low molecular weight heparin is administered up to revascularisation. The methods are also useful for treatment of unstable angina and not worsening chest pain and for treatment of non-Q-wave myocardial infarction (mild heart attack).

The invention relates to PEI (Polyetherimide) modified chitosan triply compound gene vector coated with RGD (Arginyl-Glycyl-Aspartic acid)-chondroitin sulfate and a preparation method and application thereof. The triply compound gene vector is formed by mixing RGD polypeptide modified chondroitin sulfate, pDNA and PEI grafted chitosan in the mass ratio of 15:1:4. The transfection efficiency of a chitosan vector is improved by using a PEI grafting method; by using a coating method of electronegative chondroitin sulfate, red cells in blood plasma and plasma protein can be prevented from being adsorbed and reduced and the stability of blood circulation can be enhanced; in addition, by using the special targeted RGD polypeptide to modify the chondroitin sulfate, the transmembrane capability of compound particles can be enhanced. A triply gene delivery system can be constructed by taking the PEI grafted chitosan and DNA compound particles as the core and the RGD-modified chondroitin sulfate as the casing. The preparation method is simple and convenient and has mild conditions; the modified chitosan is used as a gene vector, so that the transfection efficiency is high and the cytotoxicity is low; in addition, the invention can effectively prevent the adsorption to the red cells and electronegative macromolecules, has favorable body fluid circulating stability and is hopeful to be used for gene treatment clinical experiments.

Methods and devices for determining factor Xa inhibitors, in particular heparins and fractionated or low-molecular-weight heparins, as well as direct factor Xa inhibitors in blood samples. The methods include contacting a blood sample with a detection reagent that contains at least one thrombin substrate having a peptide residue that can be cleaved by thrombin and is amidically bound via the carboxyl end to an electrogenic substance, and with a known amount of factor X reagent and an activator reagent which induces the conversion of factor X into factor Xa. Subsequently, in a second step, the amount or activity of the electrogenic substance that is cleaved from the thrombin substrate by the factor Xa-mediated thrombin activation and/or the time course thereof is determined as the measurement signal using electrochemical methods. In a third step, the amount of the factor Xa inhibitor in the sample of the blood to be analyzed or a measured quantity that correlates therewith, in particular a clotting time that correlates therewith, is determined on the basis of this measurement signal.

The invention relates to the use of N-desulfated heparin for treating or preventing inflammation, which is based on the experimental results in animal acute abdominal inflammation model and animal bleed model. The N-desulfated heparin's anti-inflammation activity is better than or equal to that of the low molecular weight heparin, and has low activity of anti-coagulant. From a series of N-desulfated heparin of different N-sulfur-containing, a sample of the best anti-inflammation activity and the lowest anti-coagulant activity was selected. The invention solved the problem of bleeding in the use of heparin for treating of inflammation, and provided a new pathway to use heparin to prevent and treat inflammation.

The invention belongs to the field of nano diagnosis, in particular to a method for preparing heparin-modified gold nano particles. The method for preparing the heparin-modified gold nano particles is to add low molecular weight heparin into a gold nano particle solution which is reduced by a reducing agent, and obtain the gold nano particles which are modified by the low molecular weight heparin, wherein the low molecular weight heparin is hydrosulphonyl-containing low molecular weight heparin, and the reducing agent is sodium borohydride or sodium citrate. The method adopts the hydrosulphonyl-containing low molecular weight heparin as a modifier to stabilize gold nano particles which are prepared by taking the sodium borohydride or the sodium citrate as the reducing agent, and obtains the gold nano particles with small particle diameter and uniform distribution by controlling the proportion of the hydrosulphonyl-containing low molecular weight heparin and the sodium borohydride or the sodium citrate. Moreover, the method can be applied to detection of proteins or viruses, and has the advantages of quickness and convenience compared with other virus detection methods such as an immunological method and PCR polymerase chain reaction. The invention provides a novel method for industrialized production for quick virus detection.

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.

The invention relates to the field of seaweed chemicals, in particular to a method for extracting and preparing low molecular weight fucoidin from marine brown algae. The method comprises the following steps of: soaking the brown algae serving as raw materials in water, extracting for 1.5 to 3.0 hours, filtering, desalting filtrate to ensure that the salinity of the filtrate is 0.6 to 1.0 percent, performing ultrafiltration concentration on the desalted filtrate until volume is 1/20 to 1/30 of the original volume, and taking a concentrated solution as a raw material solution for later use; and adding ethanol into the raw material solution until the concentration of the ethanol in the raw material solution is 60 to 70 percent (v/v), filtering, concentrating the obtained precipitate under reduced pressure until water content is 10 to 15 percent, and thus obtaining low-purity fucoidin. By the method, the low molecular weight fucoidin with the L-fucose content of 15 to 40 percent, the organic sulfate radical content of 20 to 40 percent and the molecular weight of less than 50,000 Daltons is obtained.

The invention discloses a method for producing low-molecular-weight heparin or ultralow-molecular-weight heparin. According to the method, heparinases selected from more than two of heparinases I, II and III are used for degrading heparin so as to produce the low-molecular-weight heparin or ultralow-molecular-weight heparin.

The invention belongs to the technical field of chitosan degradation, and concretely relates to a preparation method of low molecular weight chitosan. The preparation method of the low molecular weight chitosan comprises the following steps: immersing chitosan in a solution containing hydrogen peroxide and water-soluble humic acid for a period of time, performing filtration to obtain filter residues, freezing the filter residues three times, unfreezing the frozen filter residues, drying the unfrozen chitosan in a shady place, grinding the dried chitosan to form fine powder, and irradiating thefine powder at normal temperature under normal pressure. The preparation method of the low molecular weight chitosan can effectively reduce the radiation dosage, and the obtained product has a narrowmolecular weight distribution and a low molecular weight.